High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis

Yuji Ohno, Hideki Kitahara, Kenichi Fujii, Yukinori Kohno, Noritaka Ariyoshi, Takeshi Nishi, Yoshihide Fujimoto, Yoshio Kobayashi

Research output: Contribution to journalArticle

Abstract

Background: High on-treatment platelet reactivity (HPR) under clopidogrel treatment is frequently observed in hemodialysis (HD) patients. In such patients, 10 mg of prasugrel has reportedly inhibited platelet reactivity more adequately compared with 75 mg of clopidogrel. However, the efficacy of 3.75 mg prasugrel in Japanese HD patients is largely unknown. Methods: A total of 41 Japanese coronary artery disease patients under HD who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75 mg prasugrel. At day 14, prasugrel was switched to clopidogrel. Platelet reactivity was measured using VerifyNow assay (Accumetrics, San Diego, CA, USA) at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as HPR. Results: The PRU level on prasugrel therapy was significantly lower than that on clopidogrel therapy before switching (219.1 ± 62.3 PRU vs. 238.2 ± 68.0 PRU, p = 0.02). Although the prevalence of HPR was numerically lower on prasugrel therapy compared with clopidogrel therapy before and after switching, the differences did not reach a statistical significance (57.6% vs. 75.7% vs. 74.2%, p = 0.13). Even under prasugrel treatment, more than half of patients showed HPR. Conclusions: Although low-dose prasugrel had somewhat better antiplatelet effect than clopidogrel, it could not significantly improve the prevalence of HPR in Japanese HD patients. Higher doses of prasugrel might be needed to achieve adequate platelet inhibition in this high thrombotic risk population.

Original languageEnglish
JournalJournal of cardiology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

clopidogrel
Chronic Kidney Failure
Renal Dialysis
Blood Platelets
Therapeutics
Prasugrel Hydrochloride

Keywords

  • Antiplatelet therapy
  • Hemodialysis
  • High platelet reactivity
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. / Ohno, Yuji; Kitahara, Hideki; Fujii, Kenichi; Kohno, Yukinori; Ariyoshi, Noritaka; Nishi, Takeshi; Fujimoto, Yoshihide; Kobayashi, Yoshio.

In: Journal of cardiology, 01.01.2018.

Research output: Contribution to journalArticle

Ohno, Yuji ; Kitahara, Hideki ; Fujii, Kenichi ; Kohno, Yukinori ; Ariyoshi, Noritaka ; Nishi, Takeshi ; Fujimoto, Yoshihide ; Kobayashi, Yoshio. / High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. In: Journal of cardiology. 2018.
@article{ee129dcd46f94b619e5b722922ea9804,
title = "High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis",
abstract = "Background: High on-treatment platelet reactivity (HPR) under clopidogrel treatment is frequently observed in hemodialysis (HD) patients. In such patients, 10 mg of prasugrel has reportedly inhibited platelet reactivity more adequately compared with 75 mg of clopidogrel. However, the efficacy of 3.75 mg prasugrel in Japanese HD patients is largely unknown. Methods: A total of 41 Japanese coronary artery disease patients under HD who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75 mg prasugrel. At day 14, prasugrel was switched to clopidogrel. Platelet reactivity was measured using VerifyNow assay (Accumetrics, San Diego, CA, USA) at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as HPR. Results: The PRU level on prasugrel therapy was significantly lower than that on clopidogrel therapy before switching (219.1 ± 62.3 PRU vs. 238.2 ± 68.0 PRU, p = 0.02). Although the prevalence of HPR was numerically lower on prasugrel therapy compared with clopidogrel therapy before and after switching, the differences did not reach a statistical significance (57.6{\%} vs. 75.7{\%} vs. 74.2{\%}, p = 0.13). Even under prasugrel treatment, more than half of patients showed HPR. Conclusions: Although low-dose prasugrel had somewhat better antiplatelet effect than clopidogrel, it could not significantly improve the prevalence of HPR in Japanese HD patients. Higher doses of prasugrel might be needed to achieve adequate platelet inhibition in this high thrombotic risk population.",
keywords = "Antiplatelet therapy, Hemodialysis, High platelet reactivity, Percutaneous coronary intervention",
author = "Yuji Ohno and Hideki Kitahara and Kenichi Fujii and Yukinori Kohno and Noritaka Ariyoshi and Takeshi Nishi and Yoshihide Fujimoto and Yoshio Kobayashi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jjcc.2018.07.001",
language = "English",
journal = "Journal of cardiology",
issn = "0914-5087",

}

TY - JOUR

T1 - High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis

AU - Ohno, Yuji

AU - Kitahara, Hideki

AU - Fujii, Kenichi

AU - Kohno, Yukinori

AU - Ariyoshi, Noritaka

AU - Nishi, Takeshi

AU - Fujimoto, Yoshihide

AU - Kobayashi, Yoshio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: High on-treatment platelet reactivity (HPR) under clopidogrel treatment is frequently observed in hemodialysis (HD) patients. In such patients, 10 mg of prasugrel has reportedly inhibited platelet reactivity more adequately compared with 75 mg of clopidogrel. However, the efficacy of 3.75 mg prasugrel in Japanese HD patients is largely unknown. Methods: A total of 41 Japanese coronary artery disease patients under HD who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75 mg prasugrel. At day 14, prasugrel was switched to clopidogrel. Platelet reactivity was measured using VerifyNow assay (Accumetrics, San Diego, CA, USA) at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as HPR. Results: The PRU level on prasugrel therapy was significantly lower than that on clopidogrel therapy before switching (219.1 ± 62.3 PRU vs. 238.2 ± 68.0 PRU, p = 0.02). Although the prevalence of HPR was numerically lower on prasugrel therapy compared with clopidogrel therapy before and after switching, the differences did not reach a statistical significance (57.6% vs. 75.7% vs. 74.2%, p = 0.13). Even under prasugrel treatment, more than half of patients showed HPR. Conclusions: Although low-dose prasugrel had somewhat better antiplatelet effect than clopidogrel, it could not significantly improve the prevalence of HPR in Japanese HD patients. Higher doses of prasugrel might be needed to achieve adequate platelet inhibition in this high thrombotic risk population.

AB - Background: High on-treatment platelet reactivity (HPR) under clopidogrel treatment is frequently observed in hemodialysis (HD) patients. In such patients, 10 mg of prasugrel has reportedly inhibited platelet reactivity more adequately compared with 75 mg of clopidogrel. However, the efficacy of 3.75 mg prasugrel in Japanese HD patients is largely unknown. Methods: A total of 41 Japanese coronary artery disease patients under HD who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75 mg prasugrel. At day 14, prasugrel was switched to clopidogrel. Platelet reactivity was measured using VerifyNow assay (Accumetrics, San Diego, CA, USA) at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as HPR. Results: The PRU level on prasugrel therapy was significantly lower than that on clopidogrel therapy before switching (219.1 ± 62.3 PRU vs. 238.2 ± 68.0 PRU, p = 0.02). Although the prevalence of HPR was numerically lower on prasugrel therapy compared with clopidogrel therapy before and after switching, the differences did not reach a statistical significance (57.6% vs. 75.7% vs. 74.2%, p = 0.13). Even under prasugrel treatment, more than half of patients showed HPR. Conclusions: Although low-dose prasugrel had somewhat better antiplatelet effect than clopidogrel, it could not significantly improve the prevalence of HPR in Japanese HD patients. Higher doses of prasugrel might be needed to achieve adequate platelet inhibition in this high thrombotic risk population.

KW - Antiplatelet therapy

KW - Hemodialysis

KW - High platelet reactivity

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=85050353473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050353473&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2018.07.001

DO - 10.1016/j.jjcc.2018.07.001

M3 - Article

JO - Journal of cardiology

JF - Journal of cardiology

SN - 0914-5087

ER -